NRIX - Rasio utang marang kapitalisasi buku Nurix Therapeutics

Logo korporat perusahaan Nurix Therapeutics, Inc. (NRIX)

The market trend for Nurix Therapeutics (NRIX) reflects the asset's dynamics, with its current value standing at 0.08. The business specifics remain independent of economic fluctuations or seasonality due to patent protection. Developments in protein degradation could provide the firm with exceptional pricing power. Currently, Nurix Therapeutics (NRIX) is actively expanding clinical trials, strengthening partnerships with global healthcare behemoths.

NRIX Nurix Therapeutics: Rasio utang marang kapitalisasi buku ing interval 04.07.2022 - 29.10.2026

Ringkesan rincian data analitis Nurix Therapeutics Inc (NRIX)

- rega lan prakiraan konsensus rega:
Rega saham Nurix Therapeutics|NRIX - Target konsensus
- data kapitalisasi pasar:
Nilai pasar Nurix Corp|NRIX - Total Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Nurix Therapeutics|NRIX - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku nurixtx.com|NRIX - Aset Perusahaan
- data utang lan likuiditas:
Total Utang marang Modal Nurix Therapeutics|NRIX - Tanggungan utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Nurix Pharma|NRIX - Utang kumulatif perusahaan|Utang marang nilai buku Nurix Corp|NRIX - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Nurix Therapeutics
Analisis kabeh metrik perusahaan:NRIX, Nurix Therapeutics
Produk dadi Nurix Corp

The ratio of total liabilities to the book value of equity determines the degree of financial leverage and the stability of the issuer's financing structure. By analyzing the debt-to-book capitalization trend, an investor assesses the default risk of Nurix Therapeutics (NRIX), which is critical amid geopolitical disruptions in chemical component supplies and challenges with international patent protection that limit the company's liquidity.

Pesaing Nurix Therapeutics (NRIX)

Genmab A/S - Utang-utang marang kapitalisasi buku|exelixis.com - Utang marang nilai buku|NUVL (Nuvalent) - Rasio utang marang kapitalisasi buku|KYMR: Utang-utang marang nilai buku|IDEAYA Bio (IDYA) - Rasio utang marang kapitalisasi buku|ELVN (Enliven Corp) - Rasio utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku ORIC (ORIC Pharmaceuticals)|Utang-utang marang nilai buku relaytx.com|TYRA: Utang-utang marang kapitalisasi buku|Utang marang aset resik Verastem Oncology VSTM|GLUE: Utang marang nilai buku|CGEM - Utang-utang marang nilai buku|Utang marang nilai buku Immuneering Corporation (IMRX)|c4therapeutics.com (CCCC) - Rasio utang marang aset resik|BDTX - Utang marang nilai buku|Repare Therapeutics, Inc. (RPTX) - Utang marang modal buku|PMVP (PMV Pharma) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku KPTI|Propanc Biopharma Inc (PPCB) - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik cyclacel.com (BGMS)|AADI (Aadi Bioscience, Inc.) - Utang-utang marang kapitalisasi buku|Utang marang aset resik Aileron Therapeutics Inc ALRN|BPMC (Blueprint Medicines Corp) - Utang-utang marang kapitalisasi buku|GlycoMimetics, Inc. (GLYC) - Utang-utang marang nilai buku|SWTX - Utang marang nilai buku